GBA2 and Parkinson disease: However, most GBA2 inhibitors are in development for Parkinson’s disease: ALU1811 is in preclinical development by Biogen and Alectos for Parkinson’s disease, and the GCS and GBA2 inhibitor nizubaglustat is in development for PD [326].